Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer
Small cell lung cancers (SCLC) are comprised of heterogeneous subtypes marked by lineage-specific transcription factors, including ASCL1, NEUROD1, and POU2F3. POU2F3-positive SCLC, ∼12% of all cases, are uniquely dependent on POU2F3 itself; as such, approaches to attenuate POU2F3 expression may represent new therapeutic opportunities. Here using genome-scale screens for regulators of POU2F3 expression and SCLC proliferation, we define mSWI/SNF complexes, including non-canonical BAF (ncBAF) complexes, as top dependencies specific to POU2F3-positive SCLC. Notably, clinical-grade pharmacologic mSWI/SNF inhibition attenuates proliferation of all POU2F3-positive SCLCs, while disruption of ncBAF via BRD9 degradation is uniquely effective in pure non-neuroendocrine POU2F3-SCLCs. mSWI/SNF maintains accessibility over gene loci central to POU2F3-mediated gene regulatory networks. Finally, chemical targeting of SMARCA4/2 mSWI/SNF ATPases and BRD9 decrease POU2F3-SCLC tumor growth and increase survival in vivo . Taken together, these results characterize mSWI/SNF-mediated global governance of the POU2F3 oncogenic program and suggest mSWI/SNF inhibition as a therapeutic strategy for SCLC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2024) vom: 24. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Duplaquet, Leslie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 08.02.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2024.01.21.576304 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368174506 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368174506 | ||
| 003 | DE-627 | ||
| 005 | 20240208232218.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240208s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2024.01.21.576304 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1284.xml |
| 035 | |a (DE-627)NLM368174506 | ||
| 035 | |a (NLM)38328215 | ||
| 035 | |a (PII)2024.01.21.576304 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Duplaquet, Leslie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Small cell lung cancers (SCLC) are comprised of heterogeneous subtypes marked by lineage-specific transcription factors, including ASCL1, NEUROD1, and POU2F3. POU2F3-positive SCLC, ∼12% of all cases, are uniquely dependent on POU2F3 itself; as such, approaches to attenuate POU2F3 expression may represent new therapeutic opportunities. Here using genome-scale screens for regulators of POU2F3 expression and SCLC proliferation, we define mSWI/SNF complexes, including non-canonical BAF (ncBAF) complexes, as top dependencies specific to POU2F3-positive SCLC. Notably, clinical-grade pharmacologic mSWI/SNF inhibition attenuates proliferation of all POU2F3-positive SCLCs, while disruption of ncBAF via BRD9 degradation is uniquely effective in pure non-neuroendocrine POU2F3-SCLCs. mSWI/SNF maintains accessibility over gene loci central to POU2F3-mediated gene regulatory networks. Finally, chemical targeting of SMARCA4/2 mSWI/SNF ATPases and BRD9 decrease POU2F3-SCLC tumor growth and increase survival in vivo . Taken together, these results characterize mSWI/SNF-mediated global governance of the POU2F3 oncogenic program and suggest mSWI/SNF inhibition as a therapeutic strategy for SCLC | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a So, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Ying, Alexander W |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xinyue |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yixiang |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Xintao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Shilpa |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Xiaoli S |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Qi, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Somerville, Tim D D |e verfasserin |4 aut | |
| 700 | 1 | |a Heiling, Hillary |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzola, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Yenarae |e verfasserin |4 aut | |
| 700 | 1 | |a Zoller, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Vakoc, Christopher R |e verfasserin |4 aut | |
| 700 | 1 | |a Doench, John G |e verfasserin |4 aut | |
| 700 | 1 | |a Forrester, William C |e verfasserin |4 aut | |
| 700 | 1 | |a Abrams, Tinya |e verfasserin |4 aut | |
| 700 | 1 | |a Long, Henry W |e verfasserin |4 aut | |
| 700 | 1 | |a Niederst, Matthew J |e verfasserin |4 aut | |
| 700 | 1 | |a Kadoch, Cigall |e verfasserin |4 aut | |
| 700 | 1 | |a Oser, Matthew G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2024) vom: 24. Jan. |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:24 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2024.01.21.576304 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 24 |c 01 | ||